BeiGene Ltd.

BeiGene Ltd. logo
🇺🇸United States
Ownership
Public
Established
2010-01-01
Employees
10K
Market Cap
$22.1B
Website
http://www.beigene.com
stocktitan.net
·

BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of ...

BeiGene's TEVIMBRA® approved in Israel for OESCC after prior chemotherapy; over 900,000 patients globally prescribed TEVIMBRA.
medpagetoday.com
·

No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer

Preoperative chemoradiotherapy did not improve survival over perioperative chemotherapy alone in resectable gastric and gastroesophageal junction adenocarcinoma, according to TOPGEAR data. Median overall survival was 46.4 months vs 49.4 months, with no significant differences in progression-free survival. However, preoperative chemoradiotherapy significantly improved pathological outcomes, including complete response rates and tumor downstaging.
massbio.org
·

New Report Highlights Global Trends and Advances in Chronic Lymphocytic Leukemia

Novotech's report on Chronic Lymphocytic Leukemia (CLL) highlights global clinical trial activity, treatment options, and funding. CLL incidence varies, with Europe and North America leading. Treatment includes targeted therapies and immunotherapies. Over 1,000 trials since 2019, with North America and Asia-Pacific leading. Key advancements include BTKis, BCL-2 inhibitors, and CAR T-cell therapy. Challenges include high costs and drug resistance.
massbio.org
·

In-Depth Report on Global Oesophageal Cancer Clinical Trials Now Available

Novotech's report on oesophageal cancer (OC) highlights global clinical trial activity, rising incidence, innovative treatments, and significant funding, with Asia leading in cases and China and the USA in investment.
empr.com
·

August 2024 Recap: Drug Pipeline Updates

Various drugs and their statuses are listed, including IN-001 for anaphylaxis (Fast Track), Finereonone for heart failure (Phase 3), Tirzepatide for heart failure and obesity (Phase 3), TMB-001 for congenital ichthyosis (Phase 3), Bentracimab for ticagrelor reversal (Priority Review), Fabhalta for immunoglobulin A nephropathy (accelerated approval), RLS-0071 for acute graft-vs-host disease (Fast Track and Orphan Drug), CHIKV VLP for chikungunya (Priority Review), Diazoxide choline for Prader-Willi syndrome (Priority Review), Mirdametinib for neurofibromatosis type 1 (Priority Review), Setmelanotide for genetic obesity (Priority Review), AR882 for gout (Fast Track), SPN-830 for Parkinson disease (NDA review), BGB-16673 for chronic lymphocytic leukemia (Fast Track), Cabozantinib for neuroendocrine tumors (NDA review), Linvoseltamab for multiple myeloma (Complete Response Letter), Nivolumab plus ipilimumab for hepatocellular carcinoma (BLA review), Midomafetamine for PTSD (Complete Response Letter), and Tezepelumab-ekko for COPD (Breakthrough Therapy).

Risk Adjusted Net Present Value: What is the current valuation of BeiGene's BGB-16673

BGB-16673, a heterobifunctional PROTAC targeting BTK and CRBN, is forecasted to generate $252 mn annually by 2037. Developed by BeiGene, it treats various lymphomas and leukemias. BeiGene's FY2023 revenue was $2,458.8 mn, up 73.7% YoY, with an operating loss of $844.8 mn. The rNPV model, considering R&D risks, is available for purchase.
benzinga.com
·

Innovent Bio hopes for plus-sized profits from obesity drug

Innovent Biologics' earnings report shows revenue up 46% to 3.95 billion yuan, but net loss surges 182% to 393 million yuan. The delay in sales approval for anti-obesity drug mazdutide and the sudden retirement of R&D chief Liu Yongjun dampen investor enthusiasm. Innovent's focus shifts to cardiovascular and metabolic drugs, with mazdutide and teprotumumab in the pipeline.
targetedonc.com
·

The Targeted Pulse: Good News for Advanced CLL/SLL With BGB-16673 Receiving Fast

BGB-16673 received FDA fast-track designation for R/R CLL/SLL, potentially eligible for accelerated approval. Sonrotoclax combined with zanubrutinib showed improved responses in R/R CLL/SLL. Lurbinectedin vs topotecan data in ES-SCLC explored. Financial toxicity addressed through a tumor board. Clinicians discuss paclitaxel vs docetaxel in HER2-positive breast cancer.
© Copyright 2024. All Rights Reserved by MedPath